Skip to main content
. 2020 Oct 22;15(1):1072–1082. doi: 10.1515/med-2020-0157

Figure 1.

Figure 1

Correlation of SRPX2 with chemotherapeutic efficacy of PC patients. (a) The PC patients (n = 243) were tracked as partial remission (PR, n = 151), stable disease (SD, n = 64) and progressive disease (PD, n = 28). (b) Pre-chemotherapeutic SRPX2 level was compared between PC patients of PR group and ones of SD + PD group, and post-chemotherapeutic SRPX2 level was also contrasted between the two crowds. *P < 0.05. (c) Pre- and post-chemotherapeutic SRPX2 levels were compared, respectively, among total PC patients, ones of PR group and ones of SD + PD group. *P < 0.05.